Novo Nordisk Pharmatech

Activities: Ingredients Research & Development

Trending Articles

  1. Navigating AI Integration in medical device manufacturing: risks, requirements and best practices This article explores the regulatory, technical and strategic considerations associated with integrating AI into medical devices, highlighting SaMD classification, compliance...
  2. Destination Russia for new NYK Logistics warehouse Logistics specialist NYK is expanding its market presence with the launch of new warehousing operation in Moscow, Russia.
  3. BASF announces up to 20% price increase on pharmaceutical excipients and selected APIs BASF Pharma Solutions has implemented an immediate global price adjustment of up to 20% across its pharmaceutical excipients and selected active pharmaceutical ingredients...
  4. Adragos Pharma acquires Sanofi's Maisons-Alfort sterile fill-finish facility to strengthen European injectables network Global CDMO Adragos Pharma has completed the acquisition of one of Europe's largest sterile injectables manufacturing sites from Sanofi in Maisons-Alfort, France, adding...
  5. Pfizer agrees sale of consumer healthcare business to J&J Pfizer Inc has reached an agreement to sell its consumer healthcare business to Johnson & Johnson (J&J) for US$16.6bn (euro13.2bn) in cash.

Upcoming event

Making Pharmaceuticals

21–22 April 2026 | Exhibition | Coventry, UK See all

Related Content

Regulatory

FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions

Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or water restrictions, with clinical trial participants on the highest dose losing an average of 27 pounds
You need to be a subscriber to read this article.
Click here to find out more.
Analysis

Semaglutide patent cliff: pharma industry braces for impact

With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Pharmaceutical

Novo Nordisk and Hims end GLP-1 spat, strike deal to sell Wegovy and Ozempic

The pair have reached an agreement under which the telehealth company can sell Novo's Ozempic and Wegovy, ending a legal dispute that flared last month
Manufacturing

Novo Nordisk plans Ireland expansion to manufacture oral Wegovy for global markets

The company is preparing to scale production capacity at its Athlone facility as strong US uptake of its oral obesity therapy supports a broader strategy to expand global supply and compete in the fast-growing GLP-1 market
Regulatory

Hims & Hers backs down on oral GLP-1 copycat after FDA pressure

Facing threats of legal action from Wegovy manufacturer Novo Nordisk and an FDA probe, the health and wellness company has decided to abandon its plans to offer a GLP-1 copycat
Drug Delivery

Indonesia looks to oral GLP-1s as it battles rising obesity

Novo Nordisk's oral GLP-1 therapy for chronic weight management could help the country deliver injectable-comparable weight loss alongside cardiovascular risk-reduction benefits for its expanding population
Finance

Global consortium launches to accelerate antibiotic discovery

The $60m consortium backed by the Gates Foundation, Novo Nordisk Foundation and Wellcome aims to speed the discovery of next-generation antibiotics to tackle the growing threat of antimicrobial resistance
Subscribe now